MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
October 19 2021 - 10:30AM
Business Wire
MyMD is pursuing high value opportunities in a
massive healthcare market with no known competing FDA-approved
drugs for treating aging disorders and extending healthy
lifespan
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan, announced today that it will present at
the Dawson James Securities 6th Annual Small Cap Growth Conference
on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The
conference is being held at the Wyndham Grand Jupiter at
Harbourside Place in Jupiter, Florida.
MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will
discuss the multiple indications for each of MyMD’s novel drug
candidates, MYMD-1 and Supera-CBD. A webcast of the presentation
will be available live and on demand for 90 days after the
conference.
About MYMD-1 MYMD-1’s primary purpose is to slow the
aging process and extend healthy lifespan, and it is also showing
promise as a potential treatment for post- COVID-19 complications
and as an anti-fibrotic and anti-prolific therapeutic. MYMD-1 has
shown effectiveness in regulating the immune system by performing
as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a
driver of chronic inflammation. Unlike other therapies, MYMD-1 has
been shown to selectively block TNF-α when it becomes overactivated
in autoimmune diseases and cytokine storms, but not block it from
doing its normal job of being a first responder to any routine type
of moderate infection. MYMD-1’s ease of oral dosing is another
differentiator compared to currently available TNF-α blockers, all
of which require delivery by injection or infusion. No approved TNF
inhibitor has ever been dosed orally. In addition, the drug is not
immunosuppressive and has not been shown to cause the serious side
effects common with traditional therapies that treat inflammation.
MyMD expects to launch two Phase 2 trials during the current
quarter for MYMD-1 – one for delaying aging and prolonging healthy
lifespan, and the other for post- COVID-19 depression and cytokine
elevation.
About Supera-CBD Supera-CBD is MyMD’s pre-clinical
patented synthetic cannabidiol (CBD) derivative that is being
developed as a pharmaceutical drug to address anxiety, pain, and
neurodegeneration. Supera-CBD targets the cannabinoid receptor type
2 (CB2), a protein mainly expressed in the immune system and which
is associated with the therapeutic effects of CBD, including its
anxiolytic, anticonvulsant, antipsychotic, neuroprotective and
anti-inflammatory properties. CB2 receptors do not create an
intoxicating negative psychotropic reaction (e.g. a high). In
contrast, CB1 is usually expressed in the brain and distributed
throughout the central nervous system to deliver an intoxicating
effect. A vast majority of CBD developers are pursuing compounds
targeted to CB2 that have minimal CB1 affinity. MyMD’s Supera-CBD,
with low CB1 affinity and four-fold increased CB2 binding, is 8,000
times more potent a CB2 agonist (activator) than regular CBD. The
Company believes that Supera-CBD is currently on a path toward
human clinical trials as a therapy for epilepsy, followed by
chronic pain.
About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals,
Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company
committed to extending healthy lifespan, is focused on developing
two novel therapeutic platforms that treat the causes of disease
rather than only addressing the symptoms. MYMD-1 is a drug platform
based on a clinical stage small molecule that regulates the immune
system to control TNF-α, which drives chronic inflammation, and
other pro-inflammatory cell signaling cytokines. MYMD-1 is being
developed to delay aging, increase longevity, and treat autoimmune
diseases and COVID-19- associated depression. The Company’s second
drug platform, Supera-CBD, is being developed to treat chronic
pain, addiction and epilepsy. Supera-CBD is a novel synthetic
derivative of cannabidiol (CBD) and is being developed to address
and improve upon the rapidly growing CBD market, which includes
both FDA approved drugs and CBD products not currently regulated as
drugs. For more information, visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2021, filed by MyMD on August 16,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005195/en/
Investor: Robert Schatz (646) 421-9523 rschatz@mymd.com
www.mymd.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024